All In Biotech

Drug Trial Radar · NCT03071341

Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I

An Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Patients With Mucopolysaccharidosis I Who Were Previously Enrolled in Studies With AGT-181

Last checked: Nov 20, 2026Latest source record: Mar 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Oct 2016

Primary completion

Feb 1, 2018

Study completion Feb 1, 2018

Sponsor

Lead sponsor
ArmaGen, IncIndustry
Sponsor type
Industry
First posted
Mar 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AGT-181 is a fusion protein containing alpha-L-iduronidase that is intended to deliver the enzyme peripherally and to the brain, when administered intravenously. This is a long term safety and tolerability study of AGT-181 in patients with MPS I who completed the previous 26-week study, AGT-181-101. Information on the biological activity of the investigational drug will also be collected.

Conditions

  • Mucopolysaccharidosis I

Interventions

  • AGT-181Drug

    Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. number of patients with adverse events as a measure of safety and tolerabilityTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • HCPA - Hospital das Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.